Search | Search by Center | Search by Source | Keywords in Title
Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K, Smith SC, Stone NJ, Petersen LA, Ballantyne CM. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 Jan 15; 139(3):410-412.